Plain-English translation of NCT07441642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication, can slow or stop vision loss in people with geographic atrophy—a progressive eye disease that causes blind spots in the center of vision. Researchers will compare three different doses of the medication against a placebo (dummy treatment) to find the dose that works best and is safest.
Geographic atrophy is a serious form of age-related macular degeneration that currently has no proven treatment to slow its progression. This study aims to find out if this new medication can help preserve vision and slow the disease in people who are at risk of significant vision loss.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the medication at one of three dose levels or a placebo, and neither you nor the study team will know which one you're getting. You will attend multiple clinic visits where your vision will be checked and your eyes will be photographed or scanned to see if the medication is slowing the disease. The study will help researchers understand which dose works best and how safe the treatment is.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States